🔎 Trials Near Me

Home › Kanser sa Suso › Virginia › Norfolk

Pag-aaral pangklinika para sa Kanser sa Suso sa Norfolk, VA

16 pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Norfolk (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

The Vanguard Study: Testing a New Way to Screen for Cancer

Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
  • Sentara Norfolk General Hospital, Norfolk
Edad 45 hanggang 75 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06995898

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Nagre-recruitPhase 3
  • Virginia Oncology Associates, Norfolk
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06982521

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Nagre-recruitPhase 3
  • Virginia Oncology Associates, Norfolk
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • Sentara Norfolk General Hospital, Norfolk
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Nagre-recruitPhase 2
  • Virginia Oncology Associates, Norfolk
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07102381

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Nagre-recruitPhase 1/2
  • Virginia Oncology Associates, Norfolk
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07701941

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Nagre-recruitPhase 3
  • Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07060807

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Nagre-recruitPhase 3
  • Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06966700

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Nagre-recruitPhase 3
  • Clinical Trial Site, Norfolk
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07085767

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Nagre-recruitPhase 1/2
  • Virginia Cancer Institute, Norfolk
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT05386108

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Nagre-recruitPhase 3
  • Virginia Oncology Associates, Norfolk
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT05232916

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Nagre-recruitPhase 1/2
  • USOR Virginia Oncology Associates, Norfolk
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT05579366

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Nagre-recruitPhase 2
  • Virginia Oncology Associates, Norfolk
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT05748834

Pag-aaral para sa Kanser sa Suso sa ibang lungsod

Iba pang pag-aaral sa Norfolk

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.